Bausch + Lomb to Present Scientific Data and Analyses at Upcoming Eye Care Meetings

Bausch + Lomb announced that seven scientific posters involving the company's products, as well as data from the company's Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meetings of the American Academy of Optometry in Boston (Nov. 3-6, 2021) and American Academy of Ophthalmology in New Orleans (Nov. 12-15, 2021). The company will also host several promotional education events.

"Bausch + Lomb is committed to creating opportunities for eye care professionals to learn more about our products, as well as gain valuable insights, such as those we have provided for more than a decade through our unique ARMOR study, the only ongoing surveillance study that evaluates profiles and trends in antibiotic resistance among common ocular bacterial pathogens across the United States," Joe Gordon, U.S. president, Bausch + Lomb, said in a company news release. "Doing so allows us to educate and inform eye care professionals so they can continue to address the evolving needs of their patients."

In addition to data from the company's ARMOR study, the presentations will include analyses on Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use, which received approval by the FDA in October 2021, and Bausch + Lomb INFUSE Multifocal contact lenses.*

The full schedule of scientific poster and clinical presentations, as well as the list of promotional education events is as follows: 

American Academy of Optometry

Scientific Posters

• "2020 Results from the Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) Surveillance Study." Sanfilippo et al.
• "Clinical Performance of a Novel Multifocal Contact Lens." Schafer et al.
• "In Vitro Antibiotic Resistance among Bacterial Pathogens Sourced from the Cornea in ARMOR." Sanfilippo et al.

Featured Promotional Education Events

• Wednesday, Nov. 3
  • "Industry Innovations Lunch & Learn – Practice Pearls & Innovations"
    12:00 to 12:55 p.m. ET at the Westin Boston Seaport District (425 Summer Street, Boston) During the program, Art Epstein, O.D., Ben Gaddie, O.D., Kerry Giedd, O.D., and Gina Wesley, O.D., will share practical patient cases using products from across the Bausch + Lomb Consumer Health Care, Vision Care and Pharmaceutical portfolios.

• • "Masters Forum: Crossroads in the Clinical Care of Red Eyes"
    6:30 to 9:00 p.m. ET at Davio's (26 Fan Pier Boulevard, Boston)
    Art Epstein, O.D., will review many of the most common causes of red and inflamed eyes, differential diagnosis and appropriate treatment options. Attendees can visit https://na.eventscloud.com/website/22747/ to register in advance.

• Thursday, Nov. 4
  • "Innovations in Inflammation and IOP Control"
    8:00 to 8:45 a.m. ET at the Omni Boston Hotel at the Seaport (450 Summer Street, Boston)
    Program chairs, Michael Chaglasian, O.D., and Mile Brujic, O.D., will review the science and clinical studies behind VYZULTA^® (latanoprostene bunod ophthalmic solutions), 0.024% and LOTEMAX^® SM (loteprednol etabonate ophthalmic gel) 0.38%, as well as their personal perspective on both products.

• • "Innovations in Inflammation and IOP Control"
    6:30 p.m. to 9:00 p.m. ET at Del Frisco's Double Eagle Steak House (250 Northern Avenue, Suite 200, Boston)
    Paul Karpecki, O.D., and Justin Schweitzer, O.D., will discuss two of the company's pharmaceutical advancements; LOTEMAX^® SM (loteprednol etabonate ophthalmic gel), 0.38%, and VYZULTA^® (latanoprostene bunod ophthalmic solutions), 0.024%. Attendees can visit https://na.eventscloud.com/website/31567/ to register in advance.

• Friday, Nov. 5
  • "Latest AREDS2 10-Year Study Results"
    8:00 to 8:45 a.m. ET at the Omni Boston Hotel at the Seaport (450 Summer Street, Boston)
    During this session, Jeffry Gerson, O.D., will discuss the National Eye Institute's (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2) and what the data means for eye care professionals and their patients who have moderate to advance Age-Related Macular Degeneration (AMD). 

American Academy of Ophthalmology

Scientific Posters

• "In Vitro Antibiotic Resistance among Aqueous and Vitreous Humor Bacterial Isolates Collected in the ARMOR Study." Asbell et al.
• "Post-Hoc Analysis of Suprachoroidal CLS-TA vs. Rescue Therapies in Macular Edema Associated with Noninfectious Uveitis." Henry et al.
• "Evaluation of Visual and Anatomic Temporal Biomarkers in Uveitic Macular Edema." Grewal et al.
• "Uveitic Macular Edema: Visual Function and Ocular Anatomy by Severity of Vision Loss." Reddy et al.

Featured Promotional Education Events

• Friday, Nov. 12
  • "Latest AREDS2 10-Year Study Results"
    9:00 to 10:00 a.m. CT at the New Orleans Marriott Warehouse Arts District (859 Convention Center Blvd, New Orleans, in the Cypress Ballroom 2)
    During this session, Rishi Singh, M.D., will discuss the NEI's 10-Year Follow-on Study Results of AREDS2 and what the data means for eye care professionals and their patients who have moderate to advanced AMD. 

• Saturday, Nov. 13
  • "Mastering Astigmatism Management: iTrace & enVista^® Toric"
    6:30 to 9:30 p.m. CT at Annunciation Restaurant (1016 Annunciation Street, New Orleans)
    Mitchell Schultz, M.D., and Dee Stephenson, M.D will discuss intraocular lens options, including the enVista^® Toric, how surgeons can enhance patient education related to astigmatism and the confidence that can be achieved when combining both the iTrace and enVista^® Toric technologies.